EA202090459A1 - METHODS FOR TREATMENT OF MALIGNANT TUMORS USING FARNESIL TRANSFERASE INHIBITORS - Google Patents
METHODS FOR TREATMENT OF MALIGNANT TUMORS USING FARNESIL TRANSFERASE INHIBITORSInfo
- Publication number
- EA202090459A1 EA202090459A1 EA202090459A EA202090459A EA202090459A1 EA 202090459 A1 EA202090459 A1 EA 202090459A1 EA 202090459 A EA202090459 A EA 202090459A EA 202090459 A EA202090459 A EA 202090459A EA 202090459 A1 EA202090459 A1 EA 202090459A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- blasts
- bone marrow
- methods
- malignant tumors
- treatment
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение относится к области терапии злокачественных опухолей. Конкретно, настоящее изобретение относится к способам лечения злокачественной опухоли у субъекта, имеющего клинические признаки хоминга в костном мозге миелоидных клеток, включая нейтропению, изолированную нейтропению, низкий процент бластов в периферической крови в присутствии или в отсутствие высокого процента бластов в костном мозге и/или низкое соотношение бластов в периферической крови и бластов в костном мозге с использованием ингибитора фарнезилтрансферазы (FTI), включающим определение того, является ли субъект, вероятно, способным отвечать на лечение FTI, на основании гематологических характеристик, указывающих на хоминг в костном мозге миелоидных клеток.The present invention relates to the field of therapy for malignant tumors. Specifically, the present invention relates to methods for treating cancer in a subject having clinical signs of myeloid cell homing in the bone marrow, including neutropenia, isolated neutropenia, a low percentage of blasts in peripheral blood in the presence or absence of a high percentage of blasts in the bone marrow, and / or low the ratio of peripheral blood blasts to bone marrow blasts using a farnesyl transferase inhibitor (FTI), comprising determining whether a subject is likely to respond to FTI treatment based on hematological characteristics indicative of myeloid cell homing in the bone marrow.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862646292P | 2018-03-21 | 2018-03-21 | |
PCT/US2018/045478 WO2019032489A1 (en) | 2017-08-07 | 2018-08-07 | Methods of treating cancer with farnesyltransferase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090459A1 true EA202090459A1 (en) | 2020-09-29 |
Family
ID=72616019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090459A EA202090459A1 (en) | 2018-03-21 | 2018-08-07 | METHODS FOR TREATMENT OF MALIGNANT TUMORS USING FARNESIL TRANSFERASE INHIBITORS |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA202090459A1 (en) |
-
2018
- 2018-08-07 EA EA202090459A patent/EA202090459A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201992220A1 (en) | COMBINED THERAPY FOR TREATMENT OR PREVENTION OF TUMORS | |
EA201890009A1 (en) | EZH2 INHIBITORS FOR TREATING LYMPHOMA | |
RU2014110228A (en) | DIAGNOSTIC MARKERS | |
EP4085919A3 (en) | Compositions and methods to treat cancer | |
PH12019501942A1 (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
EA201790502A1 (en) | HYSTON DIMETHYLASE INHIBITORS | |
Kwon et al. | Combinatorial effects of an epigenetic inhibitor and ionizing radiation contribute to targeted elimination of pancreatic cancer stem cell | |
MX2022016355A (en) | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors. | |
Suer et al. | Characterization of stem-like cells directly isolated from freshly resected laryngeal squamous cell carcinoma specimens | |
MX2022010512A (en) | Bcl-2 protein inhibitors. | |
MX2022014326A (en) | Multispecific proteins. | |
El-Hadaad | Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer | |
ATE478076T1 (en) | AZAXANTHONES FOR THE TREATMENT OF TUMORS | |
CL2020003204A1 (en) | Treatment of stage iii nsclc and mitigation of pathological conditions associated with treatment | |
EA202190862A1 (en) | METHODS OF TREATMENT | |
GB2523211A (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
Gao et al. | Knockdown of MPP8 suppresses cell proliferation via regulation of HOXA5 in non-small cell lung cancer cells | |
EA202090459A1 (en) | METHODS FOR TREATMENT OF MALIGNANT TUMORS USING FARNESIL TRANSFERASE INHIBITORS | |
PH12020550042A1 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
CY1111522T1 (en) | 84P2A9: SPECIFIC TO PROTECTOR AND TYPES OF PROTEIN EXPRESSIVED IN HIGH PROTECTIVE CANCER | |
Yerlikaya | Expression of heme oxygenase-1 in response to proteasomal inhibition | |
MX2021003265A (en) | Treatment methods. | |
BR112022026247A2 (en) | METHOD TO ENHANCE THE THERAPEUTIC EFFECTIVENESS OF AN IMMUNOTHERAPY AGENT, METHOD OF TREATMENT OF CANCER AND METHOD OF INHIBITING THE GROWTH OF A CANCER CELL | |
MX2021002882A (en) | Targeting egln1 in cancer. | |
AR112674A1 (en) | CANCER TREATMENT METHODS WITH FARNESILTRANSFERASE INHIBITORS |